These previous studies suggest that combination therapy targeting NSD2 together with inhibition of PI-3 Kinase, AR, EZH2, and/or DNA repair mechanisms, all of which are themselves targetable and highly relevant for prostate cancer, may prove to be efficacious for treatment of metastatic prostate cancer. The gene discussed is AR; the disease is prostate cancer.